Vivek Subbiah shared the following post by Chadi Nabhan, Medical Director of The University of Chicago Medical Center, on X, adding the following:

“Congrats to Chadi Nabhan
for the insightful hem/onc pulse for heme docs! Heard it was amazing for the Heme docs from several colleagues Naveen Pemmaraju, Toyosi Odenike, Ruben A. Mesa, Sanam Loghavi, Rafael Fonseca, Vincent Rajkumar, Joseph Mikhael, Saad Z. Usmani, Naval Daver, Aaron Goodman.

Solid tumor docs, feeling the FOMO yet? Let’s get that Onc side updates rolling! Toni Choueiri, Sumanta K. Pal, Balazs Halmos Ready ??”

Quoting Chadi Nabhan’s post:

“Only at the HOPLive24 meeting in Chicago where you could spot Vincent Rajkumar playing guitar while Aaron Goodman attempting to sing. Science & Fun only at HOPLive24
Thanks to all faculty who traveled here and safe trip home.”

Source: Vivek Subbiah/X and Chadi Nabhan/X

Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.

Dr. Vivek Subbiah has served as the principal investigator in over 100 phase I/II trials and co-investigator in over 200 clinical trials and is known for his leadership in several first-in-human and practice-changing studies that directly led to approvals from the FDA, European Medicines Agency, and other agencies across the world. He is an expert in tumor agnostic precision oncology and leads the BRAF and RET tissue agnostic studies to FDA approval.